Found 25 Breast Cancer trials
A listing of Breast Cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.
This is a pragmatic randomized clinical trial in which patients with locally advanced breast cancer will be randomized to either proton or photon therapy and followed longitudinally for cardiovascular morbidity and mortality, health-related quality of life (HRQOL), and cancer control outcomes. We hypothesize that proton therapy, as part of multi-modality …
This is a pilot study in patients with known or suspected primary or metastatic breast cancer with one lesion that is 1.5 cm in diameter or greater may be eligible for this study. Patients may participate in this study if they are at least 18 years of age. Up to …
This study will test the experimental drug, ZEN003694, in combination with a marketed drug, talazoparib (Talzenna®), in patients with triple negative breast cancer (TNBC). Among the questions it will seek to answer are: 1. What are well-tolerated doses of ZEN003694 and talazoparib that can be given together without causing significant …
Our study is a Phase 1Ib/2 clinical trial to evaluate the safety and feasibility of the combination of radiotherapy (RT) in a single fraction of 7 Gy with pembrolizumab in patients with operable breast cancer. We will employ a Simon Two Stage design to evaluate the safety, feasibility, and efficacy …
Subjects with breast cancer starting treatment with anthracyclines/trastuzumab will be enrolled and their risk of cardiotoxicity calculated. If elevated risk, they will be randomized to intervention with carvedilol for 1 year vs usual care. Low risk subjects will be usual care. All subjects will be followed with serial echo, survey, …
Request for collaborative review: WIRB serving as IRB of record.
To evaluate progression-free survival (PFS) using traditional RECIST critiera with the combination of fulvestrant and palbociclib vs. fulvestrant alone in patients with advanced HR+/HER2- breast cancer that has progressed despite prior CDK4/6 inhibition and endocrine therapy.
